Prilosec OTC Patent Extension Submission Pending At PTO
This article was originally published in The Tan Sheet
Executive Summary
AstraZeneca appears to be building its case to ward off eventual private label competition for Prilosec OTC upon expiration of Hatch/Waxman exclusivity
You may also be interested in...
Generic Prilosec OTC ANDA Filed By Perrigo Partner Dexcel; AstraZeneca Sues
Perrigo has acquired marketing rights for a potential generic version of Prilosec OTC, but litigation against the firm's partner Dexcel Pharma by AstraZeneca could block generic OTC omeprazole through 2019
Generic Prilosec OTC Capsules Suitable For ANDA Submission – FDA
FDA clears the way for an ANDA filing for capsules equivalent to Prilosec OTC tablets (omeprazole magnesium 20mg) in a July 6 response to a suitability petition
Prilosec OTC Forced Name Change Rejected As FDA Clears Pending Petitions
A lack of data supporting consumer confusion claims between nonprescription Prilosec and the eponymous Rx version is cited by FDA in a letter denying a citizen petition. The petitioner sought an agency-mandated name change